Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Every Certificate of Analysis we've ingested from volterasciences.com, what each tests for, and what's missing. Sourced back to the original COA URLs — no hosting, no editorial.
Each row is one peptide. Columns show whether at least one COA from this vendor for that peptide tests for that property. Endotoxin and sterility are usually the gap.
| Peptide | COAs | Avg purity | HPLC | MS/MALDI | NMR | Endotoxin | Sterility | Metals | Microbial |
|---|---|---|---|---|---|---|---|---|---|
| 5-Amino-1MQ | 1 | 99.89% |
Most recent batches we've ingested. Each row links to the original COA file as published by the vendor.
| Peptide | Lot | Lab | Purity | Tests | Tested | |
|---|---|---|---|---|---|---|
| 5-Amino-1MQ | 5AMINO.05.02.2026 | Kovera Labs | 99.89% | MSLALUSP<71>HM | — | View |
| BPC-157 | BPC.05.02.2026 | Kovera Labs | 99.98% | MSLALUSP<71>HM | — |
How this is built: we discover every COA URL on the vendor's public testing page, fetch the file, run structured extraction, and persist what each COA actually tests for. Vendor copy isn't a signal — only the COAs themselves.
Full methodology →| AOD-9604 | 1 | 99.53% | — | — | — |
| BPC-157 | 1 | 99.98% | — | — |
| GHK-Cu | 1 | 99.98% | — |
| Glow | 1 | 99.83% | — | — |
| Klow | 1 | 99.94% | — |
| Melanotan-2 acetate | 1 | 98.70% | — | — | — |
| MOTS-C | 1 | 99.69% | — | — | — |
| Retatrutide | 2 | 99.47% | — | — | — |
| Tesamorelin | 1 | 99.78% | — | — | — |
| Tirzepatide | 3 | 99.59% | — |
| VLS-3RT | 1 | 99.86% | — |
| View |
| GHK-Cu | GHK.05.02.2026 | Kovera Labs | 99.98% | MSLALUSP<71>HM | — | View |
| Glow | GLOW.05.02.2026 | Kovera Labs | 99.83% | MSLALUSP<71>HM | — | View |
| Klow | KLOW.05.02.2026 | Kovera Labs | 99.94% | MSLALUSP<71>HM | — | View |
| Tirzepatide | VLSTR.05.17.2026 | AccumarkLabs | 99.78% | MSLALUSP<71>HM | — | View |
| Tirzepatide | VLSTR.05.17.2026 | AccumarkLabs | 99.96% | MSLALUSP<71>HM | — | View |
| VLS-3RT | VLSRT.05.17.2026 | AccumarkLabs | 99.86% | MSLALUSP<71>HM | — | View |
| Tesamorelin | TSM10.05.28.26 | ILS Labs | 99.78% | LALUSP<71>HM | 2026-06-05 | View |
| Retatrutide | RT10.05.28.26 | ILS Labs | 99.15% | LALUSP<71>HM | 2026-06-05 | View |
| Retatrutide | RT60.05.28.26 | ILS Labs | 99.78% | LALUSP<71>HM | 2026-06-05 | View |
| MOTS-C | MS40.05.28.26 | ILS Labs | 99.69% | LALUSP<71>HM | 2026-06-05 | View |
| Tirzepatide | TR60.05.28.26 | ILS Labs | 99.03% | LALUSP<71>HM | 2026-06-05 | View |
| Melanotan-2 acetate | ML20.05.28.26 | ILS Labs | 98.70% | LALUSP<71>HM | 2026-06-05 | View |
| AOD-9604 | AOD5.05.02.2026 | ILS Labs | 99.53% | LALUSP<71>HM | 2026-05-08 | View |
Disclosed Labs